Dr. Jack West recently had the privilege to spend time with Drs. Millie Das and Matthew Gubens for a series of case-based discussions regarding...
Case Based Panel Discussion - Stage 3 NSCLC Treatment Standard and the Risk of Potential Pneumonitis
We are very excited to bring to you more information through our new program regarding supportive care in cancer treatment. Arjun Gupta, MD, one of...
We are very excited to bring to you this new program on supportive care in cancer treatment. Arjun Gupta, MD, one of the GRACE Fellows Ambassador...
Two of GRACE's earliest followers, Laya Dogmetchi and Jim Celebucki, talk about how the Global Resource for Advancing Cancer Education helps cancer...
During the Targeted Therapies in Lung Cancer Patient Forum, many of our fantastic and loved attendees shared with us what they are grateful for. For our sixth video in this month of gratitude, Ann Broo shared what she is thankful for with GRACE.
- 1 of 9
- View More
At ASCO 2018, Dr. Melissa Loh presented a study titled: "Chance of Cure in Advanced Cancer: What Do Older Patients Believe and How Are These Beliefs Related to Their Preferences?". This study looked at patients and their beliefs regarding a cure for cancer, specifically in older patients with advanced cancer. Patients who are certain that they could be cured pose unique challenges for physicians and shows a need for clear communication between patients and their physicians regarding the outcome of treatment and quality of life.
Amidst all of the glowing reports about immunotherapy for lung and many other cancers, it would be understandable for patients and physicians to be tempted to rush toward prioritizing immunotherapy as the first treatment strategy to pursue. In fact ...
Probably the most immediate potentially practice-changing presentation from ASCO was the Japanese J-ALEX study in the subset of about 4-5% of...
Dr. Cathy Pietanza from Memorial Sloan Kettering Cancer Center discusses standard chemotherapy options for treatment of both sensitive and refractory small cell lung cancer (SCLC).
Repeat Biopsies and Emerging Technologies for Plasma Sampling of Mutations Seen with Acquired Resistance
Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biopsies, including plasma sampling as a "liquid biopsy" option, in the setting of acquired resistance to a driver mutation in advanced NSCLC.
- 1 of 43
- View More
This is an article from an older version of Grace: Catching Your Breath Published February 17, 2012 | By Dr. Harman Shortness of breath, air hunger,...
My wife is experiencing a second time brain tumor recurrence. She had her first occipital craniotomy back in 2011. On late Oct 2013 she began to...
It is as if my mom's digestive system is now paralyzed. No one seems to know what to do or how to give her relief from the nausea and discomfort, or...